382 related articles for article (PubMed ID: 15284715)
1. Cancer genetics knowledge and beliefs and receipt of results in Ashkenazi Jewish individuals receiving counseling for BRCA1/2 mutations.
Kelly K; Leventhal H; Marvin M; Toppmeyer D; Baran J; Schwalb M
Cancer Control; 2004; 11(4):236-44. PubMed ID: 15284715
[TBL] [Abstract][Full Text] [Related]
2. A population-based study of Ashkenazi Jewish women's attitudes toward genetic discrimination and BRCA1/2 testing.
Lehmann LS; Weeks JC; Klar N; Garber JE
Genet Med; 2002; 4(5):346-52. PubMed ID: 12394347
[TBL] [Abstract][Full Text] [Related]
3. The decision to test in women receiving genetic counseling for BRCA1 and BRCA2 mutations.
Kelly K; Leventhal H; Andrykowski M; Toppmeyer D; Much J; Dermody J; Marvin M; Baran J; Schwalb M
J Genet Couns; 2004 Jun; 13(3):237-57. PubMed ID: 15604634
[TBL] [Abstract][Full Text] [Related]
4. Subjective and objective risk of breast cancer in Ashkenazi Jewish individuals at risk for BRCA1/2 mutations.
Kelly K; Leventhal H; Marvin M; Toppmeyer D; Much J; Dermody J; Baran J; Schwalb M
Genet Test; 2004; 8(2):139-47. PubMed ID: 15345111
[TBL] [Abstract][Full Text] [Related]
5. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
Spannuth WA; Thaker PH; Sood AK
Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394
[TBL] [Abstract][Full Text] [Related]
6. Subjective and objective risk of ovarian cancer in Ashkenazi Jewish women testing for BRCA1/2 mutations.
Kelly KM; Senter L; Leventhal H; Ozakinci G; Porter K
Patient Educ Couns; 2008 Jan; 70(1):135-42. PubMed ID: 17988821
[TBL] [Abstract][Full Text] [Related]
7. Impact of educational print materials on knowledge, attitudes, and interest in BRCA1/BRCA2: testing among Ashkenazi Jewish women.
Schwartz MD; Benkendorf J; Lerman C; Isaacs C; Ryan-Robertson A; Johnson L
Cancer; 2001 Aug; 92(4):932-40. PubMed ID: 11550168
[TBL] [Abstract][Full Text] [Related]
8. Hereditary breast/ovarian cancer--pitfalls in genetic counseling.
Dagan E; Gershoni-Baruch R
Clin Genet; 2001 Oct; 60(4):310-3. PubMed ID: 11683778
[TBL] [Abstract][Full Text] [Related]
9. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
11. Cancer Risk Information Sharing: The Experience of Individuals Receiving Genetic Counseling for BRCA1/2 Mutations.
Chopra I; Kelly KM
J Health Commun; 2017 Feb; 22(2):143-152. PubMed ID: 28112991
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer.
Schubert EL; Mefford HC; Dann JL; Argonza RH; Hull J; King MC
Genet Test; 1997; 1(1):41-6. PubMed ID: 10464624
[TBL] [Abstract][Full Text] [Related]
13. Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.
Bluman LG; Rimer BK; Regan Sterba K; Lancaster J; Clark S; Borstelmann N; Iglehart JD; Winer EP
Psychooncology; 2003; 12(5):410-27. PubMed ID: 12833555
[TBL] [Abstract][Full Text] [Related]
14. Effect on perceived control and psychological distress of genetic knowledge in women with breast cancer receiving a BRCA1/2 test result.
Brédart A; Kop JL; De Pauw A; Caron O; Fajac A; Noguès C; Stoppa-Lyonnet D; Dolbeault S
Breast; 2017 Feb; 31():121-127. PubMed ID: 27837705
[TBL] [Abstract][Full Text] [Related]
15. Health behaviors among Ashkenazi Jewish individuals receiving counseling for BRCA1 and BRCA2 mutations.
Quach J; Porter K; Leventhal H; Kelly KM
Fam Cancer; 2009; 8(3):241-50. PubMed ID: 19184534
[TBL] [Abstract][Full Text] [Related]
16. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
Oddoux C; Struewing JP; Clayton CM; Neuhausen S; Brody LC; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K
Nat Genet; 1996 Oct; 14(2):188-90. PubMed ID: 8841192
[TBL] [Abstract][Full Text] [Related]
17. Predictors of participation in psychosocial telephone counseling following genetic testing for BRCA1 and BRCA2 mutations.
Halbert CH; Wenzel L; Lerman C; Peshkin BN; Narod S; Marcus A; Corio C; Demarco T; Bellamy S
Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):875-81. PubMed ID: 15159322
[TBL] [Abstract][Full Text] [Related]
18. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer.
Armstrong K; Micco E; Carney A; Stopfer J; Putt M
JAMA; 2005 Apr; 293(14):1729-36. PubMed ID: 15827311
[TBL] [Abstract][Full Text] [Related]
19. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
[TBL] [Abstract][Full Text] [Related]
20. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.
Frey MK; Sandler G; Sobolev R; Kim SH; Chambers R; Bassett RY; Martineau J; Sapra KJ; Boyd L; Curtin JP; Pothuri B; Blank SV
Gynecol Oncol; 2017 Jul; 146(1):123-128. PubMed ID: 28495237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
